TiE Inflect 2018 Announces Lantern Pharma as a 2018 TiE50 Finalist
26 April 2018 - 1:22AM
Business Wire
Lantern Pharma is excited to announce that it has been selected
as a "2018 TiE50 Finalist" for the prestigious TiE50 Awards Program
recognizing the world's most innovative tech startups. This awards
competition is part of TiE Inflect 2018, the world's largest
conference for tech entrepreneurs.
“We are honored to have been selected as a 2018 TiE50 Finalist
for the esteemed TiE50 Awards Program from more than 7000 companies
all around the world. Founded in 2013, Lantern Pharma is rethinking
the cancer drug development process, tailoring multiple promising
precision drug programs to the right subgroup of cancer patients
through use of their RADRTM platform (Response Algorithm for Drug
Rescue and Positioning). Right patient stratification is still
considered by many in pharma as the holy grail. Lantern is
disrupting this using seamless integration of relevant existing
data, generation of new clean data closely modeling real world
evidence and very focused artificial intelligence technology
application to further model this data and distill into meaningful
information that can identify & stratify right patients with
high accuracy.
"Lantern is currently progressing 3 clinical stage drugs in
using this technology. Lantern also have a growing number of
partnerships with non-profits, and Academia. We look forward to
sharing ideas with the other Finalists, applicants and participants
at TiE Inflect 2018.” - Arun Asaithambi, Co-Founder
"TiE50 has become a global brand that attracts thousands of tech
startups worldwide. This year, we screened more than 7400 companies
from 28 countries and selected the best-of-breed as our "2018 TiE50
Finalists". These companies are finalists in the ultimate runoff
for the 50 winners. Our program has gained notoriety over the past
decade as a competition run with the highest level of integrity and
vigorous screening and judging by domain experts." - Kamal Anand,
TiE50 Program Chair
"As a 26-year not-for-profit dedicated to fostering
entrepreneurship and with a global footprint of half million
entrepreneurs, enterprise executives, and investment professionals,
we pride in the fact that we are one of very few competitions
without any pay-to-play incentives." - Ram K. Reddy, President, TiE
Silicon Valley
About Lantern Pharma Inc
Lantern Pharma is a late clinical stage precision oncology
company that is using proprietary tech platform called RADR to
identify drug specific complex genetic signatures (potential CDX)
for potential responders identification and stratification with a
high prediction accuracy to conduct focused precision clinical
trials. RADR is integrating any existing clinical data, with data
generated from wet-lab approach closely modeling real world
evidence/clinical trials and artificial intelligence to identify
genetic signatures and right responders. Lantern's approach can
improve success of the drug, lower developmental costs and time
many folds vs traditional drug developmental processes.
About TiE Inflect 2018:
TiE Inflect (previously TiEcon) is the world's largest
conference for entrepreneurs and intrapreneurs with participation
from top technology companies, leading venture capital firms, and
global services providers. TiEcon 2017 attracted 5400+ attendees
from across the world - including CEOs of established companies to
first-time entrepreneurs creating new companies, to leading
investment professionals and corporate executives. The conference
was listed by Worth Magazine as one of the 10 best conferences for
ideas and entrepreneurship along with TED and the World Economic
Forum. For more information, please
visit http://www.tieinflect.org.
About TiE:
The Indus Entrepreneurs (TiE) is a not-for-profit founded in
1992 in the Silicon Valley by a group of successful entrepreneurs,
corporate executives, and senior professionals. TiE is the world's
largest network of tech entrepreneurs. We are a cohesive global
network with a footprint of half million entrepreneurs, enterprise
executives, investment professionals, and other accomplished
individuals. We operate from 60 cities in 18
countries. http://www.tieeco.org.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180425006862/en/
Lantern PharmaArun Asaithambiarun@lanternpharma.com